T Cell Polarization toward TH2/TFH2 and TH17/TFH17 in Patients with IgG4-Related Disease

Aurélie Grados1,2†, Mikael Ebbo1,2†, Christelle Piperoglou2,3, Matthieu Groh4,5, Alexis Regent4,5, Maxime Samson6,7, Benjamin Terrier4,5, Anderson Loundou8, Nathalie Morel4,5, Sylvain Audia6,7, François Maurier9, Julie Graveleau10,11, Mohamed Hamidou10,11, Amandine Forestier12, Sylvain Palat13, Emmanuelle Bernit1, Bernard Bonotte6,7, Catherine Farnarier1, Jean-Robert Harlé1,2, Nathalie Costedoat-Chalumeau4,5, Frédéric Vély2,3‡ and Nicolas Schleinitz1,2*‡

1 AP-HM, Service de Médecine Interne, Hôpital de la Timone, Marseille, France, 2 Aix-Marseille Université, CNRS, INSERM, Centre d’Immunologie de Marseille-Luminy, Marseille, France, 3 AP-HM, Service d’Immunologie, Hôpital de la Conception, Marseille, France, 4 AP-HM, Service de Médecine Interne, CHU Cochin, AP-HP, Paris, France, 5 Université Paris Descartes, Paris, France, 6 Service de Médecine Interne, CHU le Bocage, Dijon, France, 7 Université de Bourgogne, Dijon, France, 8 AP-HM, Unité d’Aide Méthodologique, Aix-Marseille Université, Marseille, France, 9 Service de Médecine Interne, Hôpital Sainte Blanche, Metz, France, 10 Service de Médecine Interne, CHU de Nantes, Nantes, France, 11 Université de Nantes, Nantes, France, 12 Service d’Immunologie clinique, Groupe hospitalier mutualiste, Grenoble, France, 13 Service de Médecine Interne, CHU Dupuytren, Limoges, France

IgG4-related disease (IgG4-RD) is a fibro-inflammatory disorder involving virtually every organ with a risk of organ dysfunction. Despite recent studies regarding B cell and T cell compartments, the disease’s pathophysiology remains poorly understood. We examined and characterized subsets of circulating lymphocytes in untreated patients with active IgG4-RD. Twenty-eight consecutive patients with biopsy-proven IgG4-RD were included in a prospective, multicentric study. Lymphocytes’ subsets were analyzed by flow cytometry, with analysis of TH1/TH2/TH17, TFH cells, and cytokine release by peripheral blood mononuclear cells. Results were compared to healthy controls and to patients with primary Sjögren’s syndrome. Patients with IgG4-RD showed an increase of circulating T regulatory, TH2, TH17, and CD4+CXCR5+PD1+TFH cell subsets. Accordingly, increased levels of IL-10 and IL-4 were measured in IgG-RD patients. TFH increase was characterized by the specific expansion of TFH2 (CCR6−CXCR3−), and to a lesser extent of TFH17 (CCR6+CXCRC3+) cells. Interestingly, CD4+CXCR5+PD1+ TFH cells normalized under treatment. IgG4-RD is characterized by a shift of circulating T cells toward a TH1/TH17 polarization. This immunological imbalance might be implicated in the disease’s pathophysiology. Treatment regimens targeting such T cells warrant further evaluation.

Keywords: IgG4-related disease, T helper cells, T follicular helper cells, plasmablasts, Sjögren’s syndrome

INTRODUCTION

IgG4-related disease (IgG4-RD) is a newly recognized condition characterized by mass-forming lesions involving various tissues (1). The disease more frequently affects males over 50 years of age (2–4). The unifying finding of the disease is the pathological lesion characterized by dense lymphoplasmacytic infiltrates mainly consisting of CD4+ T cells and numerous IgG4+ plasma cells
associated with fibrosis (5). Tertiary germinal center formation is also frequently observed in diseased tissues.

Mikulicz’s disease, otherwise considered as a disease manifestation of primary Sjögren’s syndrome (pSS) (6) is also part of the spectrum of IgG4-RD. It has now been clearly demonstrated that despite common features shared by both diseases, clinical, biological, pathological, and immunohistological findings differ between pSS and IgG4-RD (7). Yet, in daily practice, pSS remains a frequent differential diagnosis of IgG4-RD.

Despite ongoing genetic and mechanistic studies, the pathogenesis of IgG4-RD remains poorly understood. Rather than a vector of tissue damage, IgG4 is considered to be a marker of disease activity (5). However, elevated levels of serum IgG4 have also been reported in other conditions, and approximately 30% of patients with biopsy-proven IgG4-RD have normal serum levels of IgG4 (8). Hence, the identification of novel biomarkers is a timely topic in the field of IgG4-RD.

Besides studies regarding B cells and immunoglobulin biology, careful attention is currently being paid on the role of T cells in the disease. Conflicting results have been reported regarding the polarization of T helper (T H ) cells in IgG4-RD, especially in patients with pancreatic involvement and Mikulicz’s disease (9, 10). Because regulatory T cells (Treg) are a source of IL-10 and TGF-β (i.e., key cytokines involved, respectively, in the differentiation of IgG4-producing B cells and in the genesis of fibrosis), the roles of these cells have also been investigated in a few preliminary studies regarding IgG4-related hepatic and pancreatic involvements (11–13). More recently, T follicular helper cells (T FH ), an important cell subset involved in the development of germinal centers as well as in antibody production, have also been studied in a small series of IgG4-RD patients (14) suggesting changes of this compartment in the disease. Yet, these results need to be confirmed in a new and larger cohort, including patients with other than salivary and lachrymal-restricted involvements, and with a more precise phenotypic definition of T FH subsets, especially concerning PD1 molecule expression.

In this study, we investigated circulating lymphocytes in untreated patients with IgG4-RD, with a focus on T H1/T H2/ T H17 balance and PD1+ T FH cells, and compared them to pSS patients.

PATIENTS AND METHODS

Study Subjects

Patients with IgG4-RD were identified according to the Comprehensive Diagnosis Criteria (CDC) for IgG4-RD or to the International Consensus Diagnostic Criteria (ICDC) for autoimmune pancreatitis (15). Patients with pSS were identified according to the 2002 American-European Consensus Group criteria. Patients with either IgG4-RD or pSS who received steroids or disease-modifying antirheumatic drugs within 3 months prior to study entry or who received rituximab within 6 months prior to enrollment were excluded from the study. Written informed consent was obtained from all patients with IgG4-RD or pSS as well as healthy controls (HC) prospectively included in the study. The study was approved by the local ethics committee [CPP Marseille I (Comité de Protection des Personnes Marseille I)].

Immunophenotyping by Flow Cytometry

Lymphocyte populations (total lymphocytes, T cells, CD4+ T cells, CD8+ T cells, B cells, and natural killer (NK) cells) were quantified with 6-Color BD Multitest and BD Trucount Technologies (Becton Dickinson, Le Pont de Claix, France) according to the manufacturer’s instructions.

MSL (Eurobio) density centrifugation was used to separate peripheral blood mononuclear cells (PBMCs) immediately after blood sample collection. The following antibodies were used: APC-H7 anti-CD45 or V500-anti-CD45, Amcyan-anti-CD3 or APC-H7-anti-CD3, APC-H7-anti-CD4 or PE-anti-CD4, PerCP-Cy5.5-anti-CD8 or APC-anti-CD8, APC-H7-anti-CD20, V450-anti-CD45RA or PE-Cy5-anti-CD45RA, PE-Cy7-anti-CD45RO, Alexa Fluor 488-anti-CCR5, Alexa Fluor 647-anti-PDL1, PE-anti-CCR6, PE-Cy7-anti-CCR3, APC-anti-CD25 (BD Biosciences), PerCP-Cy5.5-anti-CD19, FITC-anti-CD62L (Beckman Coulter), or isotype-matched controls for 30 min.

T FH cells were defined as CD4+CD45RA-CCR5+PD1+. Three T H subsets were defined according to the expression of CCR6 and CXCR3, as follows: CCR6+CXCR3+ T H1 cells, CCR6-CXCR3+ T H2 cells, and CCR6+CXCR3- T H17 cells. Plasmablasts were defined as CD19+CD27+CD38+ naive T cells as CD4+CD45RA+CD38−, memory T cells as CD4+CD45RO+, and NK cells as CD3−CD56+.

For intracellular markers, fixed and permeabilized cells were stained using Alexa Fluor 488-anti-FoxP3 (BD Biosciences) to analyze T regulatory cells defined as CD4+FoxP3+; PE-anti-IL-17, FITC-anti-IFNγ, and APC-anti-IL-17 (BD Biosciences) were used to characterize the functionally polarized CD4+ T cell subsets after stimulation with PMA-ionomycin for 5 h according to the manufacturers’ instructions. The cells were washed with phosphate-buffered saline and then analyzed on a BD FACS Canto II.

Analysis of Cytokine Production

Levels of IL-4, IL-10, IL-17, and IFNγ in the supernatant of PBMCs following a 24-h stimulation with PMA-ionomycin were assessed using a multiplexed bead-based immunoassay (CBA® kit, BD Biosciences) following the manufacturers’ protocol.

Statistical Analysis

Continuous variables are shown as median ± SD. Multiple group comparisons were analyzed using the Kruskal–Wallis test and the Mann–Whitney U-test was used for comparison between two groups. Correlations were analyzed using Spearman’s correlation coefficient. The Wilcoxon test was used to analyze the changes in values over time. Statistical analyses were performed with Prism 6 (GraphPad Software, San Diego, CA, USA).

For multiple testing, adjusted p-values were calculated using the false discovery rate procedure with the PROC MULTTEST statement (16). Statistical tests for multiple testing were made with the SAS 9.4 software.

RESULTS

Patients’ Characteristics

Patients with IgG4-RD included in this study fulfilled the CDC (n = 27) or the ICDC criteria (n = 1). Clinical, biological, and
pathological characteristics of these patients are reported in Tables 1 and 2. Mean age was 63.6 ± 15, 57 ± 13, and 59 ± 17.3 years in patients with IgG4-RD, pSS (n = 21), and HC (n = 28), respectively. Male gender was overrepresented in patients with IgG4-RD as compared to pSS and HC (85.5% versus 23 and 57%).

IgG4 levels were >1.35 g/l (mean 7.9 ± 6.1 g/l) in 82% of patients with IgG4-RD, median IGE level was 627 ± 1,092 UI/l and median eosinophil count 443 ± 499 cells/µl (19% of patients had >500 cells/µl) in IgG4-RD patients. Most patients with IgG4-RD (67%) were analyzed at the first flare of the disease. Organ involvement at the time of analysis included lymph nodes (n = 17), lung (n = 10), pancreas (n = 8), retroperitoneal fibrosis (n = 5), kidney (n = 5), salivary glands (n = 4), orbit (n = 3), and bile ducts (n = 2), and 64% of patients with IgG4-RD presented with ≥2 organs involved (Table 1).

### Lymphocytic Subsets in Patients with IgG4-RD

Analysis of patients with IgG4-RD showed no difference in the number and proportion of CD4+, CD8+ T cell subsets, and NK cells compared to HC (Figure 1A). Interestingly, both the number (1,685 ± 29.1 pg/ml versus 20.8 ± 3.8 and 24.2 ± 9.2 pg/ml; p = 0.009 and p = 0.03, respectively) (Figure 2C). T_{H1}, T_{H2}, and T_{H17} Cell Distribution in Patients with IgG4-RD

To analyze the distribution of functionally polarized CD4+ T cell subsets in patients with IgG4-RD, PBMCs were stimulated for 5 h using PMA-ionomycin (Figures 3A,B). The percentage of IL-4-producing CD4+ T cells (T_{H2}) was significantly higher in patients with IgG4-RD compared to HC and pSS patients (3.4 ± 0.36% versus 1.5 ± 0.14 and 2.2 ± 0.5%; p < 0.0001 and p = 0.03, respectively). In addition, IL-17+ producing CD4+ T cells (T_{H17}) were significantly higher in patients with IgG4-RD compared to HC (1.0 ± 0.17% versus 0.7 ± 0.17%; p = 0.02) but not to patients with

### Table 1: General characteristics of patients with IgG4-related disease (IgG4-RD).

| n  | G | Age | Organ involvement | IgG4 g/l | IgG4-RD RI | Status |
|----|---|-----|-------------------|----------|------------|--------|
| 1  | M | 65  | Parotid, LN       | 0.59     | 6          | Relapse|
| 2  | M | 66  | RPFI, LN, lung    | 4.74     | 12         | First flare |
| 3  | M | 66  | Meninges, aorta  | 3.61     | 7          | First flare |
| 4  | M | 57  | Pancreas          | 6.3      | 6          | First flare |
| 5  | M | 78  | Kidney, LN, lung, pancreas | 21.9 | 13 | First flare |
| 6  | F | 63  | SMG, LN           | 1.56     | 9          | First flare |
| 7  | F | 80  | RPFI, lung, thyroid | 0.49     | 6          | First flare |
| 8  | M | 47  | RPFI, pancreas, lung | 1.34     | 2          | First flare |
| 9  | M | 88  | Lung, LN, RPFI   | 15.7     | 10         | First flare |
| 10 | M | 78  | Bone, LN         | 27.5     | 9          | First flare |
| 11 | M | 66  | RPFI, lung, kidney | 2.56     | 12         | First flare |
| 12 | M | 37  | Kidney, lung, pancreas, prostate, testis, LN | 18.5 | 15 | First flare |
| 13 | M | 31  | Orbit, LN, LN, pancreas, SMG | 15.5 | 12 | First flare |
| 14 | M | 80  | Mesenteritis      | 3.16     | 4          | First flare |
| 15 | F | 39  | Orbit             | 1.04     | 6          | First flare |
| 16 | M | 74  | Kidney, pancreas, LN | 3.66     | 12         | First flare |
| 17 | M | 63  | RPFI              | 7.4      | 6          | First flare |
| 18 | M | 63  | LN                | 10.9     | 6          | First flare |
| 19 | M | 52  | Pancreas, LN, bile duct | 10.2   | 9          | First flare |
| 20 | M | 78  | Pancreas          | 4.5      | 3          | First flare |
| 21 | M | 57  | Bile duct         | 1.1      | 3          | First flare |
| 22 | M | 67  | Lung, SMG, LN     | 5.84     | 9          | First flare |
| 23 | M | 82  | Kidney, SMG, LN   | 36.7     | 15         | First flare |
| 24 | M | 43  | LN, pancreas, bile duct | 22.4   | 5          | First flare |
| 25 | M | 79  | LN, pancreas      | 3.2      | 3          | First flare |
| 26 | M | 77  | Pancreas, skin    | 16.4     | 3          | First flare |
| 27 | F | 46  | Pancreas, liver, LN | 3.59     | 12         | First flare |
| 28 | M | 63  | Dacryoadenitis, LN, pancreas | 12.3 | 12 | First flare |

**F**: female; G: gender; LN: lymph nodes; M: male; n: number; RI: responder index; RPFI: retroperitoneal fibrosis; SMG: submandibular glands.

### Table 2: Pathological characteristics of patients with IgG4-RD.

| P | Tissue | DLPI | SF | OP | EO | IgG4/IgG | IgG4/CD138* |
|---|--------|------|----|----|----|----------|-------------|
| 1 | Parotid | x | x | | | 50%/IgG | >50 |
| 2 | RPFI | x | x | | | >50%/CD138 | 80 |
| 3 | Meninges | x | x | x | | 70%/CD138 | 60 |
| 4 | Pancreas | | | | | 50%/CD138 | 45 |
| 5 | Kidney | | | | | ND | 30 |
| 6 | SMG | x | x | | | >40%/IgG | 20 |
| 7 | Lung | | | | | ND | 15 |
| 8 | Pancreas, bile duct | x | x | | | >40%/IgG | 20 |
| 9 | RPFI | | | | | 50%/CD138 | 60 |
| 10 | Lymph node | x | x | x | | 80%/CD138 | 90 |
| 11 | Kidney | x | x | x | | 50%/IgG | ND |
| 12 | Kidney | | | | | 50%/CD138 | 30 |
| 13 | SMG, pancreas | x | x | x | | 90%/IgG | ND |
| 14 | Mesenteritis | | | | | 50%/CD138 | 30 |
| 15 | Orbit | | | | | ND | >10 |
| 16 | Kidney | | | | | >50%/CD138 | 40 |
| 17 | Pancreas | | | | | ND | 40 |
| 18 | Lymph node | | | | | ND | 100 |
| 19 | Bile duct | | | | | ND | >10 |
| 20 | Pancreas | | | | | >40%/CD138 | 50 |
| 21 | Bile duct | x | x | | | ND | >10 |
| 22 | Lymph node | x | x | x | | 80%/CD138 | 40 |
| 23 | Lymph node | x | x | x | | >50%/IgG | 30 |
| 24 | Pancreas | | | | | ND | >100 |
| 25 | Pancreas | | | | | ND | 80 |
| 26 | Pancreas, skin | x | x | | | >90%/CD138 | 40 |
| 27 | Liver | x | x | x | | 0 | 0 |
| 28 | SMG | x | x | | | 50%/IgG | ND |

*IgG4 plasmocyte ratio is given either from IgG4+ or total CD138+ plasmocytes. DLPI: diffuse lymphoplasmacytic infiltrate; EO: eosinophils; HPF: high power field; ND: not determined; OP: obliterative phlebitis; RPFI: retroperitoneal fibrosis; SF: storiform fibrosis; SMG: submandibular gland.*
pSS. Conversely, the proportion of T_{H1} IFNγ+ producing cells was similar in all three groups of patients.

Cytokine Secretion Profile in Patients with IgG4-RD

In order to further confirm the trend toward a T_{H1}/T_{H2} balance in IgG4-RD, PBMCs’ cytokines production following a 24-hour stimulation with PMA-ionomycin was measured using a multiplexed CBA assay. As shown in Figure 3C, higher levels of IL-4 and IL-17 were detected in patients with IgG4-RD as compared to HC and pSS patients (82.4 ± 16.8 pg/ml versus 24.1 ± 5.6 and 89.7 ± 48.1 pg/ml for IL-4; \( p < 0.0001 \) and \( p = 0.02 \), respectively; and 120.4 ± 65.4 pg/ml versus 15.5 ± 5.5 and 80 ± 49 pg/ml for IL-17; \( p = 0.006 \) and \( p = 0.01 \), respectively). No such difference was observed with levels of IFNγ.

CD4^{+}CXCR5^{+}PD1^{+} T_{FH} Are Specifically Increased in Patients with IgG4-RD

The ectopic lymphoid structures found in tissues of patients with IgG4-RD led us to investigate for the presence of T_{FH}
cells in patients’ peripheral blood. Such cells were defined as CD4⁺CXCR5⁺CD45RA⁻PD1⁺ lymphocytes (Figure 4A). This subset was significantly increased in patients with IgG4-RD when compared to HC and pSS patients in both percentages (3.7 ± 0.3% versus 1.7 ± 0.1 and 2 ± 0.2%; \( p < 0.0001 \) and \( p = 0.001 \), respectively) and numbers (35.4 ± 4.8 cells/μl versus 13.4 ± 0.9 and 13.9 ± 1.6 cells/μl; both \( p < 0.0001 \), respectively) (Figure 4B). We also evaluated PD1⁺ TFH cell number in 11 IgG4-RD patients who were treated with steroids alone (\( n = 4 \)), steroids plus azathioprine (\( n = 1 \)), or steroids plus rituximab (\( n = 6 \)). Interestingly, disease remission in these treated IgG4-RD patients was associated with reduced circulating TFH cells (Figure 4C).

**TFH2 and TFH17 Are the Main T Follicular Helper Cells Expanded in Patients with IgG4-RD**

As for T helper cells, TFH cells can be further classified into distinct subsets according to cell-surface chemokine receptor expression: TFH1 (CCR6⁻CXCR3⁺), TFH2 (CCR6⁻CXCR3⁻), and TFH17 (CCR6⁺CXCR3⁻) (Figure 5A). Among the CD4⁺CXCR5⁺PD1⁺ TFH cells, TFH2 cells were the main increased subset in patients with IgG4-RD compared to HC and pSS patients for both number and percentages (8.5 ± 1.6 cells/μl versus 2.2 ± 0.2 and 2.2 ± 0.4 cells/μl; \( p < 0.0001 \) and \( p = 0.0004 \), respectively; and 44.2 ± 2.7% versus 33.2 ± 1.6 and 35 ± 2.6%; \( p = 0.0003 \) and \( p = 0.005 \), respectively). The number of TFH17 cells was higher in patients with IgG4-RD as compared to HC and pSS patients (2.83 ± 0.6 cells/μl versus 1.4 ± 0.1 and 1.3 ± 0.3 cells/μl; \( p = 0.03 \) and \( p = 0.06 \), respectively). Last, the proportion of TFH1 cells was decreased in patients with IgG4-RD as compared with HC and pSS patients (19 ± 1.9 cells/μl versus 26.6 ± 1.4 and 27.2 ± 2.1 cells/μl; \( p = 0.002 \) and \( p = 0.003 \), respectively) (Figure 5B).

**DISCUSSION**

IgG4-related disease is characterized by tissue infiltration by numerous IgG4⁺ plasmocytes, increased numbers of circulating plasmablasts and elevated titers of both serum IgG4, IgE, as well as other IgG subclasses (2). B cell activation appears to be T cell-dependent because activated B cells harbor enhanced somatic mutation, and relapses after rituximab (a B-cell-depleting agent) are characterized by the emergence of new plasmablast clones (17). T CD4⁺ cells are numerous in disease infiltrates and are thought to trigger B cell polyclonal expansion and fibrosis. Prior studies regarding blood and/or tissue analysis of IgG4-RD patients suggest changes of T helper cells, Treg, and
more recently oligoclonal CD4<sup>+</sup> effector/memory cytotoxic T lymphocytes (9–11, 18, 19).

Hence, we conducted a systematic analysis of lymphocyte subsets in untreated patients with IgG4-RD. Major T cell subsets, including memory and naïve T cells, NK, and B cells were normal in patients with IgG4-RD compared to HC. Concordant with previous reports, plasmablast cell counts were higher in patients with IgG4-RD as compared to HC (17). Albeit not reaching significance, plasmablast cells were also higher in patients with IgG4-RD as compared to pSS patients. Next, in line with a previous study, there was a clear trend toward an increase of circulating CD4<sup>+</sup>Foxp3<sup>+</sup> Tregs in IgG4-RD patients, suggesting that in such patients Treg expansion is not restricted to diseased tissues (18). Treg were also shown to be increased in blood, without reaching significance, in an independent study (19). In IgG4-RD, Treg expansion might contribute to the genesis of fibrosis through TGF-β release and to the increase of IL-10 release by PBMCs. From that perspective, IgG4-RD is different than most autoimmune diseases where Treg are commonly decreased (20).

Over-production of T<sub>H</sub>2-related cytokines (IL-4, IL-13, and IL-5) in IgG4-RD tissues has previously been reported (11) and correlates with IgE and IgG4 class switch, blood eosinophilia, and eosinophilic infiltrates that are common features of IgG4-RD (4, 11). Hence, and despite previous studies that provided conflicting results regarding the T<sub>H</sub>1/T<sub>H</sub>2 balance in PBMCs from IgG4-RD patients, it has been suggested that T<sub>H</sub>2 cells might be key players in the disease's pathophysiology (9, 10). Yet, the central role of such cells is debated because IL-4 production upon re-stimulation has been shown to be restricted to CD4<sup>+</sup>GATA3<sup>+</sup> T cells in patients with known atopy, suggesting that the role of T<sub>H</sub>2 responses in IgG4-RD might be confounded by concomitant allergic disease (21). The present analysis of T<sub>H</sub>1, T<sub>H</sub>2, and T<sub>H</sub>17 cells in IgG4-RD showed an increase of both T<sub>H</sub>2 and T<sub>H</sub>17 cells. Interestingly, the increase of T<sub>H</sub>2 cells in the present study was not restricted to a unique organ involvement. Moreover, only 4 out of 28 patients (16%) with IgG4-RD also complied with the definition of the European Academy of Allergy and Clinical Immunology for atopy (22). T<sub>H</sub>2 and T<sub>H</sub>17 cell number, IgE levels, and eosinophil numbers were not significantly different between atopic and non-atopic patients (data not shown). Hence, according to our data, T<sub>H</sub>2 cell expansion in IgG4-RD patients cannot be restricted only to patients with concomitant atopy. Next, the analysis of cytokine release by PBMCs upon stimulation were in line with these findings and showed that patients with IgG4-RD produced higher amounts of IL-4 but also of IL-10 and IL-17 as compared with HC and patients with pSS. Both T<sub>H</sub>2 and Treg are thought to contribute to IL-4 and IL-10 release, but we did not expect to report on both high IL-17 levels and elevated T<sub>H</sub>17 cells. Analysis of the co-expression of intracellular IL-17 and IL-4 after stimulation.

**FIGURE 4 | T follicular helper cells in IgG4-related disease (IgG4-RD) patients.** Representative staining showing an expansion of CXCR5<sup>+</sup>PD1<sup>+</sup>T<sub>FH</sub> cells in untreated patients with IgG4-RD compared to a healthy individual (A). CXCR5<sup>+</sup>PD1<sup>+</sup>T<sub>FH</sub> cells percentage (left panel) and absolute numbers (right panel) are higher in IgG4-RD patients (blue lines) than in healthy controls (black lines) and Sjögren syndrome patients (orange lines) (B). Both T<sub>FH</sub> cells percentage (left panel) and absolute numbers (right panel) decrease after treatment in patients with IgG4-RD (C). Bars show the median and the 10th and 90th percentiles. If the Kruskal–Wallis test is significant, groupwise comparisons are performed by the Mann–Whitney U-test, p is considered significant when <0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
CD4 T cells showed that double positive cells were extremely rare, and therefore that the source of both cytokines were differentiated T\(_{H2}\) or T\(_{H17}\) cells (data not shown).

Extranasal germinal centers are often found in IgG4-RD tissues, and IgG4 plasmablasts harbor somatic hypermutation (17), a process occurring during B cell differentiation in germinal centers. Because T\(_{FH}\) are essential for germinal center formation and Ig class switch in humans and mice, they could be implicated in the pathogenesis of IgG4-RD (23). The circulating T\(_{FH}\) compartment in human is heterogeneous based on PD1, CCR6, and CXCR3 expression (23, 24). Here, we show that the CD4\(^+\)CXCR5\(^+\)PD1\(^+\) T\(_{FH}\) cells are specifically expanded in IgG4-RD. Interestingly, since only one patient presented with an increase of T\(_{FH}\) after treatment with rituximab, expansion is reversible in patients with IgG4-RD that are efficiently treated. Expanded PD1\(^+\) T\(_{FH}\) have been previously reported in human autoimmune diseases such as systemic lupus erythematosus, pSS, and juvenile dermatomyositis (25, 26). In the latter, both T\(_{FH2}\) and T\(_{FH17}\) are increased and correlate with plasmablast numbers and disease activity (26). In our analysis, CXCR5\(^+\)PD1\(^+\) T\(_{FH}\) cells were not expanded in untreated pSS patients but were expanded in IgG4-RD. T\(_{FH}\) expansion was mostly related to the T\(_{FH2}\) CCR6\(^-\)CXCR3\(^-\) subset and to a lesser extent to the T\(_{FH17}\) CCR6\(^+\)CXCR3\(^-\) subset. T\(_{FH2}\) and T\(_{FH17}\) cells have been shown to efficiently induce in vitro naïve B cells to proliferate and differentiate into plasmablasts and produce all IgG subclasses, in contrast to T\(_{FH1}\) (25). T\(_{FH2}\) specifically produces IL-4, IL-5, and IL-13, which are important cytokines for the class switching to IgE and IgG4. The expansion of T\(_{FH2}\) is consistent with pathological and biological abnormalities reported in IgG4-RD patients. Our study showed that T\(_{FH2}\) cell numbers correlated positively with serum IgG4 \((r = 0.64; p = 0.0004)\), IL-4 \((r = 0.55; p = 0.01)\), and IL-10 \((r = 0.49; p = 0.03)\) (Table 3). Moreover, an increase of the CD4\(^+\)CXCR5\(^+\)CD45RA\(^-\) T\(_{FH}\) and T\(_{FH2}\) cells in IgG4-RD has been reported in another series of 15 patients (14). However, PD1 expression was not analyzed. The specific expansion of CXCR5\(^+\)PD1\(^+\) T\(_{FH}\) observed in our study could be related to some unique functional properties inherent to IgG4-RD's pathogenesis. Indeed, PD1\(^+\) T\(_{FH}\) require less activation than PD1\(^-\) T\(_{FH}\) to differentiate into functional helpers and, by
opposition to PD1+ T FH. PD1+ T FH express low levels of CCR7 (24). The PD1+CCR7 low T FH population is required for T cells to migrate into B cell follicles (27). Thus the specific expansion of PD1+ T FH in IgG4-RD could be an important trigger to B cell activation, class switch, and plasmablast generation. Interestingly, it has been shown in rheumatoid arthritis that PD1+ T FH is maintained by plasmablasts by an IL-6-dependent positive feedback loop that should be investigated in IgG4-RD (28).

The findings reported in our study consist of correlations and causation of these T cells changes in the pathophysiology of IgG4-RD have to be confirmed by further functional studies. It has been recently shown in Japanese patients with predominant salivary and lachrymal glands involvement that CD4+CD45RA- CXCR5+CCR6- CXCR3+ T FH2 cells were more efficient in inducing differentiation into plasmablasts and led to higher IgG4 production by autologous naïve B cells in active, untreated IgG4-RD patients than in HC (29), suggesting a functional role of these cells in the disease. The authors found in a previous study a correlation between the increased number of circulating T FH2 cells and the number of plasmablasts (14), which was not found in our study. Conversely it is also plausible that these T cells changes are secondary to yet other unknown factor(s) (e.g., a source of TGF-β) that drives T cell differentiation and IgG4 production. In this line, mast cells have recently been shown to express IL-4, IL-10, and TGF-β (30), as well as IL-13 (31) in IgG4-RD tissues, and these innate cells could contribute to the T FH2 regulatory cytokines orientation reported in the disease.

Major cytokines involved in the early T FH differentiation process from CD4+ T cells in human, including IL-12, IL-23, and TGF-β, are also supported by other STAT3-activating cytokines including IL-6, IL-21, and IL1-β (23). In human autoimmune diseases, both T FH17 and T FH co-emerge and share a developmental mechanism induced by TGF-β. It has been proposed that abundant expression of TGF-β in inflammatory sites in human autoimmune diseases (28), where tertiary lymphoid organs are often formed, contribute to the generation of TFH and T fh17 cells (24). Hence, the expansion of these cells could be the consequence of an initial inflammatory process. In tissues, T FH17-related molecules have been reported in salivary glands of patients with IgG4-RD, albeit at low levels (32). The site where the differentiation and expansion of T FH occurs in IgG4-RD is unknown, and no link has been established with IL-1β and TGF-β producing clonal expanded CD4+SLAMF7+ CTLs (19).

Interestingly, our results showed that PD1+ T FH cells were significantly decreased in patients with IgG4-RD who were treated with either steroids alone, steroids plus azathioprine, or steroids plus rituximab, and that the decrease in PD1+ T FH cells was always associated with clinical improvement of the disease. Significant variation of T FH cells after treatment with steroids has also been recently reported in Japanese patients with modification of T FH1 cells, which we did not observe in our larger study (29). However, organ involvement was significantly different from our study. Interestingly, the PD1+ T FH subset also comprises T FH regulatory cells co-expressing Foxp3 and an imbalance of T FH/T FH Foxp3 regulatory could also be implicated in the disease’s pathophysiology and should be further explored (33).

### CONCLUSION

We show that patients with active, untreated IgG4-RD presenting with variable organ involvements present specific changes of T cells in peripheral blood. Circulating PD1+ T FH are expanded together with T FH2 and T FH17, associated with elevated IL-4, IL-10, and IL-17 release. Both PD1+ Thh2 and Thh17 subsets have been shown to be prone to migrate into B cell follicles and/or inflammatory sites and could therefore contribute to B cell activation and IgG4 class switch in IgG4-RD tissues. Yet, the precise role of these T cell changes together with the role of clonal expanded cytotoxic T cells, their interactions with B cells and other immune cells, and the induction of fibrosis remains to be further assessed in IgG4-RD. Indeed, in a near future, it is likely that specific treatments targeting T cells will be assessed in IgG4-RD.

### AUTHOR CONTRIBUTIONS

AG, ME, FV, and NS: conception and design of the work; acquisition, analysis, and interpretation of data for the work; drafting the work and revising it critically for important intellectual content. CP, CF, J-RH, and NC-C: acquisition, analysis, and interpretation of data for the work; revising the work critically for important intellectual content. All authors meet following criteria: final approval of the version to
REFERENCES

1. Kamisawa T, Zen Y, Pillai S, Stone JH. IgG4-related disease. *Lancet* (2015) 385:1460–71. doi:10.1016/S0140-6736(14)60720-0
2. Ebbo M, Daniel L, Pavic M, Sève P, Hamidou M, Andres E, et al. IgG4-related systemic disease: features and treatment response in a French cohort: results of a multicenter registry. *Medicine* (Baltimore) (2012) 91:49–56. doi:10.1097/MD.0b013e3182434d77
3. Inoue D, Yoshida K, Yoneda N, Ozaki K, Matsubara T, Nagai K, et al. IgG4-related disease: dataset of 235 consecutive patients. *Medicine* (Baltimore) (2015) 94:e680. doi:10.1097/MD.0000000000000680
4. Wallace ZS, Deshpande V, Matteo H, Mahajan VS, Kulikova M, Pillai S, et al. IgG4-related disease: clinical and laboratory features in one hundred twenty-five patients. *Arthritis Rheumatol* (2015) 67:2466–75. doi:10.1002/art.39205
5. Deshpande V, Zen Y, Chan JK, Yi EE, Sato Y, Yoshino T, et al. Consensus statement on the pathology of IgG4-related disease. *Mod Pathol* (2012) 25:1181–92. doi:10.1038/modpathol.2012.72
6. Morgan WS, Castleman B. A clinicopathologic study of Mikulicz’s disease. *Am J Pathol* (1953) 29:471–503.
7. Masaki Y, Dong L, Kurose N, Kitagawa K, Morikawa Y, Yamamoto M, et al. Proposal for a new clinical entity, IgG4-positive multorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders. *Ann Rheum Dis* (2009) 68:1310–5. doi:10.1136/ard.2008.089169
8. Carruthers MN, Khosroshahi A, Augustin T, Deshpande V, Stone JH. The diagnostic utility of serum IgG4 concentrations in IgG4-related disease. *Ann Rheum Dis* (2015) 74:14–8. doi:10.1136/annrheumdis-2013-204907
9. Miyake K, Moriyama M, Aizawa K, Nagano S, Inoue Y, Sadanaga A, et al. Peripheral CD4+ T cells showing a Th2 phenotype in a patient with Mikulicz’s disease associated with lymphadenopathy and pleural effusion. *Mod Rheumatol* (2008) 18:86–90. doi:10.1007/s11016-007-0010-3
10. Okazaki K, Uchida K, Ohana M, Nakase H, Uose S, Inai M, et al. Autoimmune-related pancreatitis is associated with autoantibodies and a Th1/Th2-type cellular immune response. *Gastroenterology* (2000) 118:573–81. doi:10.1016/S0016-5085(00)83803-2
11. Zen Y, Fujii T, Harada K, Kawano M, Yamada K, Takahira M, et al. Th2 and regulatory immune reactions are increased in immunoglobulin G4-related sclerosing pancreatitis and cholangitis. *Hepatology* (2007) 45:1538–46. doi:10.1002/hep.21697
12. Kusuda T, Uchida K, Miyoshi H, Koyabu M, Saito S, Takaoka M, et al. Involvement of inducible costimulator- and interleukin 10-positive regulatory T cells in the development of IgG4-related autoimmune pancreatitis. *Pancreas* (2011) 40:1120–30. doi:10.1097/MPA.0b013e318211cf796
13. Koyabu M, Uchida K, Miyoshi H, Sakaguchi Y, Fukui T, Ikeda H, et al. Analysis of regulatory T cells and IgG4-positive plasma cells among patients of IgG4-related sclerosing cholangitis and autoimmune liver diseases. *J Gastroenterol* (2010) 45:732–41. doi:10.1007/s00535-010-0199-3
14. Akiyama M, Suzuki K, Yamaoka K, Yatsuoka H, Takeshita M, Kaneko Y, et al. Number of circulating follicular helper 2 T cells correlates with IgG4 and interleukin-4 levels and plasmablast numbers in IgG4-related disease. *Arthritis Rheumatol* (2015) 67:2476–81. doi:10.1002/art.39209
15. Maruyama M, Watanabe T, Kanai K, Oguchi T, Muraki T, Hamano H, et al. International consensus diagnostic criteria for autoimmune pancreatitis and its Japanese amendment have improved diagnostic ability over existing criteria. *Gastroenterol Res Pract* (2013) 2013:456965–8. doi:10.1155/2013/456965
16. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J Statist Soc B* (1995) 57(1):289–300.
17. Matteo H, Mahajan VS, Torre Della E, Sekigami Y, Carruthers M, Wallace ZS, et al. De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG4-related disease. *J Allergy Clin Immunol* (2014) 134:3679–87. doi:10.1016/j.jaci.2014.03.034
18. Zen Y, Liberal R, Nakanuma Y, Heaton N, Jortberg M. Possible involvement of CCL1-CCR8 interaction in lymphocytic recruitment in IgG4-related sclerosing cholangitis. *J Hepatol* (2013) 59:1059–64. doi:10.1016/j.jhep.2013.06.016
19. Matteo H, Mahajan VS, Maehara T, Deshpande V, Wallace ZS, et al. Clonal expansion of CD4+ cytotoxic T lymphocytes in patients with IgG4-related disease. *J Allergy Clin Immunol* (2016) 138:825–38. doi:10.1016/j.jaci.2015.12.1330
20. Kleineveldt M, Haller DA. The plasticity of human Treg and Th17 cells and its role in autoimmunity. *Semin Immunol* (2013) 25:365–12. doi:10.1016/j.smim.2013.10.009
21. Torre Della E, Matteo H, Mahajan VS, Carruthers M, Pillai S, Stone JH. Prevalence of atopy, eosinophilia, and IgE elevation in IgG4-related disease. *Allergy* (2014) 69:269–72. doi:10.1111/all.12320
22. Johansson SG, Hourihan JO, Bousquet J, Bruijnzeel-Koomen C, Dreborg S, Haathela T, et al. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. *Allergy* (2001) 56:813–24. doi:10.1034/j.1398-9995.2001.00002.x-x
23. Ueno H, Banchereau J, VINUESA CG. Pathophysiology of T follicular helper cells in humans and mice. *Nat Immunol* (2015) 16:142–52. doi:10.1038/ ni.3054
24. Schmitt N, Bentebibel S-E, Ueno H. Phenotype and functions of memory Tfh cells in human and mice. *Nat Immunol* (2015) 16:142–52. doi:10.1038/ni.3054
25. Schmitt N, Bentebibel S-E, Ueno H. Phenotype and functions of memory Tfh cells in human and mice. *Nat Immunol* (2015) 16:142–52. doi:10.1038/ni.3054
26. Ueno H, Banchereau J, VINUESA CG. Pathophysiology of T follicular helper cells in humans and mice. *Nat Immunol* (2015) 16:142–52. doi:10.1038/ ni.3054
27. Haynes NM, Allen CDC, Lesley R, Ansel KM, Killeen N, Cyster JG. Role of T follicular helper 1 T cells in the pathogenesis of IgG4-related disease. *Arthritis Res Ther* (2015) 17:2016. doi:10.1186/s13075-015-0796-3
28. Takeuchi M, Sato Y, Ohno K, Takakita K, Gion Y, et al. T helper 2 and regulatory T-cell cytokine production by mast cells: a key factor in FUNDING

This study was funded by the French Ministry of Health (PHRC IR 2011–31 RC12_3608). The study was also supported by a grant from the CSL Behring Company France.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at http://journal.frontiersin.org/article/10.3389/fimmu.2017.00235/full#supplementary-material.
the pathogenesis of IgG4-related disease. *Mod Pathol* (2014) 27:1126–36. doi:10.1038/modpathol.2013.236
31. Takeuchi M, Ohno K, Takata K, Gion Y, Tachibana T, Orita Y, et al. Interleukin 13-positive mast cells are increased in immunoglobulin G4-related sialadenitis. *Sci Rep* (2015) 5:7696. doi:10.1038/srep07696
32. Maehara T, Moriyama M, Nakashima H, Miyake K, Hayashida J-N, Tanaka A, et al. Interleukin-21 contributes to germinal centre formation and immunoglobulin G4 production in IgG4-related dacryoadenitis and sialoadenitis, so-called Mikulicz’s disease. *Ann Rheum Dis* (2012) 71:2011–9. doi:10.1136/annrheumdis-2012-201477
33. Sage PT, Sharpe AH. T follicular regulatory cells. *Immunol Rev* (2016) 271:246–59. doi:10.1111/imr.12411

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Grados, Ebbo, Piperoglou, Groh, Regent, Samson, Terrier, Loundou, Morel, Audia, Maurier, Graveleau, Hamidou, Forestier, Palat, Bermit, Bonotte, Farnarier, Harlé, Costedoat-Chalumeau, Vély and Schleinitz. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.